The European Medicines Agency (EMA) has highlighted the growing importance of radiopharmaceuticals in healthcare, underlining both the opportunities and regulatory challenges associated with this rapidly evolving field. The observations are included in the Agency’s Horizon Scanning report, published in May 2026, which examines emerging trends likely to influence the future of medicines in Europe.
Radiopharmaceuticals are playing an increasingly significant role in both diagnostic imaging and targeted therapies, particularly in oncology. According to the EMA, the unique characteristics of these medicinal products require a dedicated regulatory approach that considers not only pharmaceutical legislation but also safety standards related to exposure to ionising radiation.
The report notes that radiopharmaceuticals include a broad range of products, such as radionuclide precursors, generators and kits used for in-house preparation. Their development, manufacturing, distribution and clinical use involve technical and logistical requirements that differ substantially from those of conventional medicines.
The need for greater regulatory harmonisation
As scientific knowledge and regulatory frameworks continue to evolve, the EMA stresses the importance of achieving better harmonisation at both European and global levels. Consistent regulatory approaches could facilitate innovation while maintaining high standards of quality, safety and efficacy. The Agency points out that the sector is advancing rapidly, creating new opportunities for personalised medicine but also raising complex regulatory questions. Greater alignment among authorities could help streamline development pathways and support wider patient access to innovative treatments.
Another key theme emerging from the report is the broad range of expertise required throughout the lifecycle of radiopharmaceuticals. From research and development to manufacturing, clinical application and radiation safety, these products involve specialists from multiple disciplines. This complexity makes ongoing collaboration essential. The EMA highlights the value of early and continuous dialogue among stakeholders, including developers, manufacturers, healthcare professionals, researchers and regulatory authorities. Such engagement can help regulators gain a deeper understanding of the scientific, technical and operational challenges specific to the radiopharmaceutical sector.
Supporting future innovation
The report also draws attention to the importance of securing the supply of radiopharmaceuticals. Given their critical role in diagnosis and treatment, any disruption in availability could have a direct impact on patient care. For this reason, the EMA recommends that regulators and policymakers build on the work already carried out by expert groups focused on maintaining supply chains and preventing shortages. Strengthening these efforts will be crucial as demand for radiopharmaceuticals continues to grow across Europe.
Looking ahead, the EMA considers radiopharmaceuticals a strategic area for the future of healthcare and precision medicine. To fully realise their potential, the Agency argues that regulatory systems must continue to evolve, supported by stronger stakeholder collaboration and coordinated actions to address both scientific and supply-related challenges. By fostering harmonisation, encouraging dialogue and safeguarding availability, regulators can help create an environment that supports innovation while ensuring patient safety and access to these increasingly important therapies.
